Top Markets
Coin of the day
Kinnate Biopharma Inc. Kinnate Biopharma Inc.

Kinnate Biopharma Inc.

KNTE
Clasificación en acciones #21072
Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily... Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily focused on identifying and advancing small-molecule drugs that target kinase enzymes to treat cancers defined by specific genetic markers. The company's product pipeline includes: KIN-2787: An inhibitor of rapidly accelerated fibrosarcoma (RAF), currently being developed to treat patients with lung cancer, melanoma, and other forms of solid tumors. KIN-3248: A small-molecule kinase inhibitor designed to counteract cancer-associated genetic mutations in the fibroblast growth factor receptors, specifically FGFR2 and FGFR3. KIN004 Program: This program encompasses early-stage small-molecule research, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor. Established in 2018, Kinnate Biopharma Inc. maintains its headquarters in San Francisco, California. It was formerly a division of Fount Therapeutics, LLC.
Precio por acción
$2.65
Última sincronización: 2024-04-03
Capitalización bursátil
$115.71M
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Kinnate Biopharma Inc. (KNTE)

Categoría

Historial de rendimiento por dividendo de Kinnate Biopharma Inc. (KNTE)
Rendimiento por dividendo (TTM) de Kinnate Biopharma Inc. (símbolo bursátil: KNTE) al 2026: 0
Rendimiento promedio por dividendo de los últimos 5 años: 0.00%
Historial de rendimiento por dividendo de Kinnate Biopharma Inc. (KNTE) desde 2026 hasta 2026
Rendimiento por dividendo al final de cada año (TTM)
Año Rendimiento por dividendo Cambiar
Not enough data for the provided dates.
Rendimientos por dividendo (TTM) de empresas similares o competidoras
Empresa Rendimiento por dividendo País
0.00%
US
0.00%
NL
0.00%
US
3.12%
AU
0.00%
CH